StocksMedium•4 November 2026•
1 min read
Novo Nordisk Shares Jump 6% as Wegovy Hits Key Growth Milestones
Key Facts
1Novo Nordisk shares jumped 6% following the disclosure of positive growth metrics for its Wegovy weight-loss drug.
Novo Nordisk shares jumped 6% following the disclosure of positive growth metrics for its Wegovy weight-loss drug. 247wallst.com reported that the surge was driven by investor optimism over the rapid adoption of the treatment, specifically noting that the oral version has captured approximately 80% of new prescriptions in the United States.
NVO closed at $40.19 on November 3, 2026, prior to the latest gains triggered by third-quarter results. The company has raised its free cash flow outlook to between 60 and 70 billion Danish kroner, as cumulative prescriptions surpassed the 8 million mark since the start of 2026.